Skip to main content
Journal cover image

Comparison of the efficacy of IGIV-C, 10% (caprylate/chromatography) and IGIV-SD, 10% as replacement therapy in primary immune deficiency. A randomized double-blind trial.

Publication ,  Journal Article
Roifman, CM; Schroeder, H; Berger, M; Sorensen, R; Ballow, M; Buckley, RH; Gewurz, A; Korenblat, P; Sussman, G; Lemm, G
Published in: Int Immunopharmacol
September 2003

A novel method of large-scale chromatography has been developed to improve recovery and purity of immunoglobulin G (IgG) from pooled plasma. The current study compares safety, toxicity and efficacy of two intravenous immunoglobulin products: a novel formulation, IGIV caprylate/chromatography (IGIV-C; Gamunex, 10%) and a licensed solvent/detergent-treated product, Gamimune N, 10% (IGIV-SD). The study, a randomized, double-blind, parallel group, therapeutic equivalence trial, was conducted at 25 treatment centers in Canada and the United States. Patients (n=172) having confirmed chronic primary immunodeficiency (PID), aged 1-75 years, and receiving IGIV therapy were enrolled. For 9 months, patients were treated with IGIV-C or IGIV-SD in accordance with the patient's individualized treatment regimen utilized before study entry. The primary endpoint was the proportion of patients with >or=1 validated acute sinopulmonary infection during the treatment period. Secondary endpoints included the proportion of patients with all infections, time to first infection, annual infection rates, lung function parameters, infusion-related safety and viral safety. The annual validated infection rate in the IGIV-C group was 0.18 compared to 0.43 in the IGIV-SD group (p=0.023). Nine patients receiving IGIV-C experienced validated infections, compared to 17 patients in IGIV-SD group (p=0.06). Acute sinusitis (validated plus clinically defined) was less frequent in the IGIV-C group (p=0.012). Presence of bronchiectasis did not affect efficacy. Adverse reactions were similar in frequency and severity in both groups. No evidence of viral transmission was observed. IGIV-C appears to be superior to IGIV-SD in preventing validated sinopulmonary infections, especially acute sinusitis, in patients with PID.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Int Immunopharmacol

DOI

ISSN

1567-5769

Publication Date

September 2003

Volume

3

Issue

9

Start / End Page

1325 / 1333

Location

Netherlands

Related Subject Headings

  • Treatment Outcome
  • Solvents
  • Sinusitis
  • Pneumonia
  • Middle Aged
  • Male
  • Infections
  • Infection Control
  • Infant
  • Incidence
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Roifman, C. M., Schroeder, H., Berger, M., Sorensen, R., Ballow, M., Buckley, R. H., … Lemm, G. (2003). Comparison of the efficacy of IGIV-C, 10% (caprylate/chromatography) and IGIV-SD, 10% as replacement therapy in primary immune deficiency. A randomized double-blind trial. Int Immunopharmacol, 3(9), 1325–1333. https://doi.org/10.1016/s1567-5769(03)00134-6
Roifman, Chaim M., Harry Schroeder, Melvin Berger, Ricardo Sorensen, Mark Ballow, Rebecca H. Buckley, Anita Gewurz, Phillip Korenblat, Gordon Sussman, and Georg Lemm. “Comparison of the efficacy of IGIV-C, 10% (caprylate/chromatography) and IGIV-SD, 10% as replacement therapy in primary immune deficiency. A randomized double-blind trial.Int Immunopharmacol 3, no. 9 (September 2003): 1325–33. https://doi.org/10.1016/s1567-5769(03)00134-6.
Roifman CM, Schroeder H, Berger M, Sorensen R, Ballow M, Buckley RH, et al. Comparison of the efficacy of IGIV-C, 10% (caprylate/chromatography) and IGIV-SD, 10% as replacement therapy in primary immune deficiency. A randomized double-blind trial. Int Immunopharmacol. 2003 Sep;3(9):1325–33.
Roifman, Chaim M., et al. “Comparison of the efficacy of IGIV-C, 10% (caprylate/chromatography) and IGIV-SD, 10% as replacement therapy in primary immune deficiency. A randomized double-blind trial.Int Immunopharmacol, vol. 3, no. 9, Sept. 2003, pp. 1325–33. Pubmed, doi:10.1016/s1567-5769(03)00134-6.
Roifman CM, Schroeder H, Berger M, Sorensen R, Ballow M, Buckley RH, Gewurz A, Korenblat P, Sussman G, Lemm G. Comparison of the efficacy of IGIV-C, 10% (caprylate/chromatography) and IGIV-SD, 10% as replacement therapy in primary immune deficiency. A randomized double-blind trial. Int Immunopharmacol. 2003 Sep;3(9):1325–1333.
Journal cover image

Published In

Int Immunopharmacol

DOI

ISSN

1567-5769

Publication Date

September 2003

Volume

3

Issue

9

Start / End Page

1325 / 1333

Location

Netherlands

Related Subject Headings

  • Treatment Outcome
  • Solvents
  • Sinusitis
  • Pneumonia
  • Middle Aged
  • Male
  • Infections
  • Infection Control
  • Infant
  • Incidence